Table 5.
Clinical trials with the use of ASCs
| Indication | Number of trials |
|---|---|
| Endocrine system | |
| Diabetes and its complications | 6 |
| Gastrointestinal and urogenital tract | |
| Crohn’s disease/fistula/faecal incontinence | 19 |
| Urinary incontinence | 3 |
| Renal failure | 1 |
| Liver failure | 3 |
| Ovaries failure | 1 |
| Eractile dysfunction/urethral structure | 4 |
| Ischemia | |
| Angiogenesis/Burger disease/limb ischemia | 12 |
| Vascular occlusive disease of the kidney | 1 |
| Myocardial infarction | 4 |
| Hard and soft tissues | |
| Arthritis/bone/cartilage | 24 |
| Lipodystrophy | 2 |
| Romberg disease | 1 |
| Cosmetics reconstruction | 7 |
| Other | |
| Central nervous system/keratopathy/multiple sclerosis/Parkinson’s disease/stroke | 11 |
| GvHD | 1 |
| Spinal cord injury | 4 |
| Autism | 1 |
| Heart failure | 4 |
| Frailty syndrome | 1 |
| Chronic obstructive pulmonary disease/pulmonary fibrosis | 5 |
| Dry macular degeneration/retinal degeneration | 2 |
| Pain | 2 |
| Acute respiratory distress syndrome | 1 |
| Sepsis | 1 |
On the basis of (ClinicalTrials.gov database 2015)
Adipose derived stem cells are currently used in several clinical trials. Most of them concern gastrointestinal and urogenital tract pathologies and cartilage and bone degeneration
GvHD graft versus host disease